BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2192715)

  • 1. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
    Sugiyama Y; Shimura Y; Ikeda H
    Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
    Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
    Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
    Ikeda H; Taketomi S; Sugiyama Y; Shimura Y; Sohda T; Meguro K; Fujita T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):156-62. PubMed ID: 2334455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats.
    Hayakawa T; Shiraki T; Morimoto T; Shii K; Ikeda H
    Biochem Biophys Res Commun; 1996 Jun; 223(2):439-44. PubMed ID: 8670300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
    Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
    Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone.
    Kazumi T; Hirano T; Odaka H; Ebara T; Amano N; Hozumi T; Ishida Y; Yoshino G
    Diabetes; 1996 Jun; 45(6):806-11. PubMed ID: 8635657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
    Matsuura B; Kanno S; Minami H; Tsubouchi E; Iwai M; Matsui H; Horiike N; Onji M
    J Gastroenterol; 2004; 39(4):339-45. PubMed ID: 15168245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
    J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
    Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
    Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites.
    Lam TK; van de Werve G; Giacca A
    Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E281-90. PubMed ID: 12531742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization.
    Igarashi M; Takeda Y; Ishibashi N; Takahashi K; Mori S; Tominaga M; Saito Y
    Horm Metab Res; 1997 Sep; 29(9):444-9. PubMed ID: 9370113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2009 Jan; 602(2-3):448-54. PubMed ID: 19038243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
    Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
    Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone: beyond glucose control.
    de Pablos-Velasco P
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1057-67. PubMed ID: 20670183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
    Hofmann CA; Edwards CW; Hillman RM; Colca JR
    Endocrinology; 1992 Feb; 130(2):735-40. PubMed ID: 1733721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
    Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
    Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.